New hope for advanced cancer: first human trial of GS-0201 begins

NCT ID NCT06167317

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen May 28, 2026 · Last updated Jun 11, 2026 · Updated 4 times

Summary

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 278 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chaim Sheba Medical Center
RECRUITING

Tel Litwinsky, 52621, Israel
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02459, United States
NEXT Austin
RECRUITING

Austin, Texas, 78758, United States
NEXT Dallas
RECRUITING

Irving, Texas, 75039, United States
Rambam Health Care Campus
RECRUITING

Haifa, 31096, Israel
Tel Aviv Sourasky Medical Center
RECRUITING

Tel Aviv, 6423906, Israel
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS